Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen C Bain

Showing results (41-50 of 129) with videos related to

Pageof 13
Sort By:
Diabetes, Obesity & Metabolism|November 7, 2022
The challenges and pitfalls of incorporating evidence from cardiovascular outcomes trials in health economic modelling of type 2 diabetesMarc Evans, Sasha Berry, Avideh Nazeri, et al.
The New England Journal of Medicine|November 2, 2004
Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathyAnthony H Barnett, Stephen C Bain, Paul Bouter, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|November 9, 2024
Cardiovascular, Metabolic, and Safety Outcomes with Semaglutide by Baseline Age: Post Hoc Analysis of SUSTAIN 6 and PIONEER 6Stephen C Bain, Nicolas Belmar, Søren T Hoff, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|May 9, 2024
Real-World Clinical Experience of Oral Semaglutide in a Secondary Diabetes Clinic in the UK: A Retrospective Observational StudyDavid M Williams, Barbara-Alex Alberts, Asem Sharaf, et al.
Diabetes, Obesity & Metabolism|January 7, 2020
Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular riskMansoor Husain, Stephen C Bain, Ole K Jeppesen, et al.
European Journal of Endocrinology|March 28, 2002
Association studies between the HSD11B2 gene (encoding human 11beta-hydroxysteroid dehydrogenase type 2), type 1 diabetes mellitus and diabetic nephropathyGareth G Lavery, Claire L McTernan, Stephen C Bain, et al.
Medicine and Science in Sports and Exercise|December 14, 2020
Blood Glucose Responses during Cardiopulmonary Incremental Exercise Testing in Type 1 Diabetes: A Pooled AnalysisOlivia McCarthy, Jason Pitt, Ben Wellman, et al.
The Lancet. Diabetes & Endocrinology|January 24, 2017
Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trialChristopher Sorli, Shin-Ichi Harashima, George M Tsoukas, et al.
Kidney International Reports|July 31, 2024
Effects of Once-Weekly Semaglutide on Kidney Disease Outcomes by KDIGO Risk Category in the SUSTAIN 6 TrialKatherine R Tuttle, Stephen C Bain, Heidrun Bosch-Traberg, et al.
JAMA Cardiology|November 14, 2019
Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events: A Post Hoc Analysis of a Randomized Clinical TrialSubodh Verma, Stephen C Bain, John B Buse, et al.
Pageof 13

Showing results (41-50 of 129) with videos related to

Sort By:
Pageof 13
Diabetes, Obesity & Metabolism|November 7, 2022
The challenges and pitfalls of incorporating evidence from cardiovascular outcomes trials in health economic modelling of type 2 diabetesMarc Evans, Sasha Berry, Avideh Nazeri, et al.
The New England Journal of Medicine|November 2, 2004
Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathyAnthony H Barnett, Stephen C Bain, Paul Bouter, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|November 9, 2024
Cardiovascular, Metabolic, and Safety Outcomes with Semaglutide by Baseline Age: Post Hoc Analysis of SUSTAIN 6 and PIONEER 6Stephen C Bain, Nicolas Belmar, Søren T Hoff, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|May 9, 2024
Real-World Clinical Experience of Oral Semaglutide in a Secondary Diabetes Clinic in the UK: A Retrospective Observational StudyDavid M Williams, Barbara-Alex Alberts, Asem Sharaf, et al.
Diabetes, Obesity & Metabolism|January 7, 2020
Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular riskMansoor Husain, Stephen C Bain, Ole K Jeppesen, et al.
European Journal of Endocrinology|March 28, 2002
Association studies between the HSD11B2 gene (encoding human 11beta-hydroxysteroid dehydrogenase type 2), type 1 diabetes mellitus and diabetic nephropathyGareth G Lavery, Claire L McTernan, Stephen C Bain, et al.
Medicine and Science in Sports and Exercise|December 14, 2020
Blood Glucose Responses during Cardiopulmonary Incremental Exercise Testing in Type 1 Diabetes: A Pooled AnalysisOlivia McCarthy, Jason Pitt, Ben Wellman, et al.
The Lancet. Diabetes & Endocrinology|January 24, 2017
Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trialChristopher Sorli, Shin-Ichi Harashima, George M Tsoukas, et al.
Kidney International Reports|July 31, 2024
Effects of Once-Weekly Semaglutide on Kidney Disease Outcomes by KDIGO Risk Category in the SUSTAIN 6 TrialKatherine R Tuttle, Stephen C Bain, Heidrun Bosch-Traberg, et al.
JAMA Cardiology|November 14, 2019
Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events: A Post Hoc Analysis of a Randomized Clinical TrialSubodh Verma, Stephen C Bain, John B Buse, et al.
Pageof 13